A global view of hepatocellular carcinoma: trends, risk, prevention and management
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death
worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol …
worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol …
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A Vogel, A Cervantes, I Chau, B Daniele… - Annals of …, 2018 - annalsofoncology.org
The incidence of hepatocellular carcinoma (HCC) has been rising worldwide over the last
20 years and is expected to increase until 2030 in some countries including the United …
20 years and is expected to increase until 2030 in some countries including the United …
90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE …
E Dhondt, B Lambert, L Hermie, L Huyck… - Radiology, 2022 - pubs.rsna.org
Background Transarterial chemoembolization (TACE) is the recommended treatment for
intermediate hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver …
intermediate hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver …
Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases
This guidance provides a data-supported approach to the diagnosis, staging, and treatment
of patients diagnosed with hepatocellular carcinoma (HCC). A guidance document is …
of patients diagnosed with hepatocellular carcinoma (HCC). A guidance document is …
EASL clinical practice guidelines: management of hepatocellular carcinoma
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …
Goals and targets for personalized therapy for HCC
T Couri, A Pillai - Hepatology international, 2019 - Springer
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality
worldwide and its incidence continues to rise. While cirrhosis underlies most cases of HCC …
worldwide and its incidence continues to rise. While cirrhosis underlies most cases of HCC …
Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma
J Bruix, M Reig, M Sherman - Gastroenterology, 2016 - Elsevier
Evidence-based management of patients with hepatocellular carcinoma (HCC) is key to
their optimal care. For individuals at risk for HCC, surveillance usually involves …
their optimal care. For individuals at risk for HCC, surveillance usually involves …
The diagnosis and treatment of hepatocellular carcinoma
J Hartke, M Johnson, M Ghabril - Seminars in diagnostic pathology, 2017 - Elsevier
Hepatocellular carcinoma is a leading cancer worldwide. Its incidence is increasing, and is
closely related to advanced liver disease. Cirrhosis represents the greatest risk factor for this …
closely related to advanced liver disease. Cirrhosis represents the greatest risk factor for this …
[PDF][PDF] Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data
Transarterial chemoembolization (TACE) using lipiodol‐based regimens, including the
administration of an anticancer‐in‐oil emulsion followed by embolic agents, is widely used …
administration of an anticancer‐in‐oil emulsion followed by embolic agents, is widely used …
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
J Ricke, HJ Klümpen, H Amthauer, I Bargellini… - Journal of …, 2019 - Elsevier
Background & Aims Sorafenib is the recommended treatment for patients with advanced
hepatocellular carcinoma (HCC). We aimed to compare the efficacy and safety of a …
hepatocellular carcinoma (HCC). We aimed to compare the efficacy and safety of a …